Mobileye N.V. (NYSE:MBLY) shares have a current ABR (average broker recommendation) of 3.05. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.
Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of Mobileye N.V. (NYSE:MBLY). The highest current target is $64. The lowest price target out of the polled analysts is presently $37. The consensus target price is currently noted at $58.473. Analysts may employ various techniques to help predict future stock price levels.
On the earnings front, Mobileye N.V. (NYSE:MBLY) is expected to post quarterly earnings per share of $0.18. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around 2017-06-01. Mobileye N.V. (NYSE:MBLY) most recently reported quarterly EPS of $0.14 for the quarter ending 2016-12-31. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of 16.67%.
The Wall Street analysts who cover Pfizer, Inc. (NYSE:PFE) shares are providing price target projections on the company. They project that the shares will move to $38.6 within the upcoming year. The number they've arrived at is calculated by Zacks.com, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $52 and the lowest is at $33 for the stock. This number may be different from what First Call has published for the consensus target estimate. Analysts that routinely cover the company may use varying techniques in order to create a future target price. Because of the different methods that analysts can use, targets may differ greatly between analysts.
Analyst Ratings In View
Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Pfizer, Inc. (NYSE:PFE)'s shares currently have an ABR of 2.25. A 1 rating would point to a Strong Buy, and a score of 5 would signify a Strong Sell rating. The average broker rating assists investors by providing them with a general feel for analyst sentiment on company shares. The success of analyst predictions can be tracked for institutional investors through First Call. Retail investors can use tools such as TipRanks or Marketbeat in order to track analyst performance.
During this fiscal period, Street analysts are projecting $0.65 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2017-03-31, Pfizer, Inc. (NYSE:PFE) dialed in an EPS of $0.69, creating a Surprise Factor of 2.99% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2017-08-01, the date when Pfizer, Inc. (NYSE:PFE) will release their quarterly results. A surprise factor in either direction may result in significant stock movement immediately and in the days following the release. Firms that consistently miss expectations can experience a downtrend over time. Whereas stocks that consistently outperform analyst expectations, can often see positive stock movement.